|
1
|
Martel-Pelletier J, Barr AJ, Cicuttini FM,
Conaghan PG, Cooper C, Goldring MB, Goldring SR, Jones G, Teichtahl
AJ and Pelletier JP: Osteoarthritis. Nat Rev Dis Primers.
2:160722016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Glyn-Jones S, Palmer AJ, Agricola R, Price
AJ, Vincent TL, Weinans H and Carr AJ: Osteoarthritis. Lancet.
386:376–387. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Loeser RF, Goldring SR, Scanzello CR and
Goldring MB: Osteoarthritis: A disease of the joint as an organ.
Arthritis Rheum. 64:1697–1707. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Van Spil WE, Kubassova O, Boesen M,
Bay-Jensen AC and Mobasheri A: Osteoarthritis phenotype novel
therapeutic targets. Biochem Pharmacol. 165:41–48. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
O'Neill TW, McCabe PS and McBeth J: Update
on the epidemiology, risk factors and disease outcomes of
osteoarthritis. Best Pract Res Clin Rheumatol. 32:312–326. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kalaitzoglou E, Griffin TM and Humphrey
MB: Innate immune responses and osteoarthritis. Curr Rheumatol Rep.
19:452017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kim JR, Jong Y and Hyun K: Therapeutics in
osteoarthritis based on an Understanding of its molecular
pathogenesis. Int J Mol Sci. 19:6742018. View Article : Google Scholar :
|
|
8
|
Herrero-Beaumont G, Pérez-Baos S,
Sánchez-Pernaute O, Roman-Blas JA, Lamuedra A and Largo R:
Targeting chronic innate inflammatory pathways, the main road to
prevention of osteoarthritis progression. Biochem Pharmacol.
165:24–32. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gómez R, Villalvilla A, Largo R, Gualillo
O and Herrero-Beaumont G: TLR4 signaling in osteoarthritis-finding
targets for candidate DMOADs. Nat Rev Rheumatol. 11:159–170. 2014.
View Article : Google Scholar
|
|
10
|
Rachner TD, Khosla S and Hofbauer LC:
Osteoporosis: Nowand the future. Lancet. 377:1276–1287. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Black DM and Rosen CJ: Clinical practice.
Postmenopausal osteoporosis. N Engl J Med. 374:254–262. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Manolagas SC and Jilka RL: Bone marrow,
cytokines, and bone remodeling. Emerging insights into the
pathophysiology of osteoporosis. N Engl J Med. 332:305–311. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sobacchi C, Schulz A, Coxon FP, Villa A
and Helfrich MH: Osteopetrosis: Genetics, treatment and new
insights into osteoclast function. Nat Rev Endocrinol. 9:522–536.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Almeida M, Laurent MR, Dubois V, Claessens
F, O'Brien CA, Bouillon R, Vanderschueren D and Manolagas SC:
Estrogens and androgens in skeletal physiology and pathophysiology.
Physiol Rev. 97:135–187. 2017. View Article : Google Scholar :
|
|
15
|
Khosla S, Oursler MJ and Monroe DG:
Estrogen and the skeleton. Trends Endocrinol Metab. 23:576–581.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Choi HK, Kim GJ, Yoo HS, Song DH, Chung
KH, Lee KJ, Koo YT and An JH: Vitamin C activates
osteoblastogenesis and inhibits osteoclastogenesis via
Wnt/β-catenin/ATF4 signaling pathways. Nutrients. 11:5062019.
View Article : Google Scholar
|
|
17
|
Lee KY, Kim JH, Kim EY, Yeom M, Jung HS
and Sohn Y: Water extract of Cnidii Rhizoma suppresses
RANKL-induced osteoclastogenesis in RAW 264.7 cell by inhibiting
NFATc1/c-Fos signaling and prevents ovariectomized bone loss in
SD-rat. BMC Complement Altern Med. 19:2072019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu TJ and Guo JL: Overexpression of
microRNA-141 inhibits osteoporosis in the jawbones of
ovariectomized rats by regulating the Wnt/β-catenin pathway. Arch
Oral Biol. 113:1047132020. View Article : Google Scholar
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
20
|
Ji X, Chen X and Yu X: MicroRNAs in
osteoclastogenesis and function: Potential therapeutic targets for
osteoporosis. Int J Mol Sci. 17:3492016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chou CH, Shrestha S, Yang CD, Chang NW,
Lin YL, Liao KW, Huang WC, Sun TH, Tu SJ, Lee WH, et al: miRTarBase
update 2018: A resource for experimentally validated
microRNA-target interactions. Nucleic Acids Res. 46:D296–D302.
2018. View Article : Google Scholar :
|
|
22
|
Ashburner M, Ball CA, Blake JA, Botstein
D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT,
et al: Gene ontology: Tool for the unifcation of biology. Te Gene
Ontology Consortium. Nat Genet. 25:25–29. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
David C, Mundo AF, Haw R, Milacic M,
Weiser J, Wu G, Caudy M, Garapati P, Gillespie M, Kamdar MR, et al:
The Reactome pathway knowledgebase. Nucleic Acids Res. 42(Database
issue): D472–D477. 2014. View Article : Google Scholar
|
|
24
|
Zhao J, Huang M and Zhang X, Xu J, Hu G,
Zhao X, Cui P and Zhang X: miR-146a deletion protects from bone
loss in OVX mice by suppressing RANKL/OPG and M-CSF in bone
microenvironment. J Bone Miner Res. 34:2149–2161. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kim JH, Kim EY, Lee B, Min JH, Song DU,
Lim JM, Eom JW, Yeom M, Jung HS and Sohn Y: The effects of Lycii
Radicis Cortex on RANKL-induced osteoclast differentiation and
activation in RAW 264.7 cells. Int J Mol Med. 37:649–658. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yao GQ, Troiano N, Simpson CA and Insogna
KL: Selective deletion of the soluble colony-stimulating factor 1
isoform in vivo prevents estrogen-deficiency bone loss in mice.
Bone Res. 5:170222017. View Article : Google Scholar :
|
|
27
|
Hu L, Su P, Yin C, Zhang Y, Li R, Yan K,
Chen Z, Li D, Zhang G, Wang L, et al: Microtubule actin
crosslinking factor 1 promotes osteoblast differentiation by
promoting β-catenin/TCF1/Runx2 signaling axis. J Cell Physiol.
233:1574–1584. 2018. View Article : Google Scholar
|
|
28
|
Kahler RA and Westendorf JJ: Lymphoid
enhancer factor-1 and beta-catenin inhibit Runx2-dependent
transcriptional activation of the osteocalcin promoter. J Biol
Chem. 278:11937–11944. 2003. View Article : Google Scholar : PubMed/NCBI
|
